Table 2

Univariate and multivariate analyses of MACE in the overall study population

Univariate analysisModel 1*Model 2†
VariableHR (95% CI)p ValueHR (95% CI)p ValueHR (95% CI)p Value
Age1.04 (1.02 to 1.06)<0.001
Female1.78 (1.29 to 2.47)0.0011.48 (1.02 to 2.15)0.039
eGFR0.98 (0.83 to 0.99)<0.0010.99 (0.89 to 0.99)0.0070.99 (0.98 to 0.99)0.005
LVD3.21 (2.16 to 4.78)<0.0012.81 (1.86 to 4.26)<0.0012.90 (1.92 to 4.39)<0.001
MI1.17 (0.83 to 1.66)0.374
Stroke2.20 (1.47 to 3.29)<0.0011.64 (1.05 to 2.54)0.0291.63 (1.05 to 2.54)0.031
PAD1.86 (1.24 to 2.79)0.003
HTN1.12 (0.78 to 1.60)0.539
DLp0.65 (0.48 to 0.89)0.008
DM0.90 (0.65 to 1.25)0.538
AF2.01 (1.35 to 2.99)0.001
ACS1.55 (1.23 to 2.12)0.0071.62 (1.15 to 2.28)0.0061.63 (1.16 to 2.29)0.005
LBMI 11.7–17.62.15 (1.57 to 2.93)<0.0011.51 (1.01 to 2.25)0.043
BMI 13.4–22.21.73 (1.27 to 2.36)0.0011.37 (0.97 to 1.95)0.075

  • *Model 1 included LBMI 11.7–17.6 kg/m2, age, gender, eGFR (mL/min/1.73 m2), LV dysfunction, history of stroke, history of PAD, hypertension, DLp, DM, AF and ACS on admission.

  • †Model 2 included BMI 13.4–22.2 kg/m2, age, gender, eGFR (mL/min/1.73 m2), LVD, history of stroke, history of PAD, hypertension, DLp, DM, AF and ACS on admission.

  • ACS, acute coronary syndrome; AF, atrial fibrillation; BMI, body mass index; DLp, dyslipidaemia; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; LBMI, lean body mass index; LVD, left ventricular dysfunction; MACE, major adverse cardiac event; MI, myocardial infarction; PAD, peripheral artery disease.